Natural Compound

Alpha-Lipoic Acid

(R)-1,2-Dithiolane-3-pentanoic acid (ALA/Thioctic acid)

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

300-600 mg per day

watchEffect Window

2-8 weeks for neuropathy and antioxidant endpoints.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Alpha-lipoic acid is a mitochondrial cofactor with antioxidant activity that can recycle other antioxidants. Its clearest human use is diabetic-neuropathy symptom relief.

The strongest human evidence supports alpha-lipoic acid for diabetic peripheral neuropathy symptom improvement, especially at 600 mg/day. Modern meta-analyses show more reliable reductions in symptom scores than in nerve-conduction or broader metabolic endpoints. Glucose, weight, and liver-marker claims are less consistent than neuropathy marketing often implies, so the entry should stay neuropathy-first rather than broad anti-aging or cardiometabolic.

Mitochondrial cofactor that functions as both fat- and water-soluble antioxidant. Regenerates endogenous antioxidants (vitamins C, E, glutathione). Enhances insulin signaling and glucose uptake.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Diabetic peripheral neuropathy symptom reduction
  • Antioxidant defense and regeneration of vitamins C, E, glutathione

Secondary Outcomes

  • Modest glucose-regulation support in some high-risk populations
  • Oxidative stress reduction

Safety

Contraindications and Interactions

Contraindications

  • Thiamine deficiency (ALA can increase thiamine demand, so correct deficiency before chronic use and co-supplement thiamine for chronic use)
  • Pregnancy (caution)
  • Lactation (caution)

Side effects

  • Nausea - The risk of nausea increases with higher dosages (1,200 mg/day or higher).
  • Vomiting
  • Heartburn
  • Urine odor
  • Headache
  • Abdominal pain - Abdominal pain was also experienced with a placebo. Therefore, causality cannot be established.
  • Vertigo
  • Bitter taste
  • Skin rash
  • Hypoglycemia (especially when combined with blood-glucose-lowering medications).

Interactions

  • Blood-glucose-lowering drugs (Probable/Minor) - Includes insulin, metformin, and sulfonylureas. Additive effects may increase hypoglycemia risk, so monitor glucose closely.
  • Thyroid medications (Theoretical/Unknown) - Alpha-lipoic acid may reduce T4 to T3 conversion. Monitor thyroid symptoms and labs.
  • Chemotherapy agents (Theoretical/Unknown) - Antioxidant co-use during active chemotherapy is debated. Avoid concurrent use without oncologist approval.
  • Biotin (Vitamin B7) (Theoretical/Unknown) - Shares an intestinal transporter with alpha-lipoic acid. Separate timing and supplement biotin with chronic use.
  • Blood-thinning drugs (Theoretical/Unknown) - Possible additive antiplatelet effect may increase bleeding risk with anticoagulants or antiplatelets.
  • Blood-glucose-lowering supplements (Theoretical/Unknown) - Theoretical additive glucose-lowering effects may increase hypoglycemia risk.

Avoid if

  • Active thiamine deficiency
  • Uncontrolled diabetes without medical supervision
  • Pregnancy without clinician guidance
  • Lactation without clinician guidance
  • People using blood-glucose-lowering drugs without monitoring

Evidence

Study-level References

alpha-lipoic-acid-SRC-001Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Hsieh RY, Huang IC, Chen C, Sung JY. Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy. A Meta-Analysis and Systematic Review. Nutrients. 2023;15(16):3634. doi:10.3390/nu15163634. PMID:37630823.

Population: Adults with diabetic sensorimotor peripheral neuropathy across 10 randomized controlled trials

Dose protocol: Oral alpha-lipoic acid 600 to 1800 mg/day across 10 randomized diabetic polyneuropathy trials

Key findings: Oral alpha-lipoic acid improved total symptom scores, neurological disability scores, and global satisfaction, but it did not clearly improve vibration threshold, lower-limb impairment scores, or nerve-conduction-study outcomes.

Notes: Best corrective anchor for keeping alpha-lipoic acid focused on symptom relief rather than broad anti-aging or cardiometabolic claims.

Paper content

This meta-analysis pooled 10 randomized trials of oral alpha-lipoic acid for diabetic polyneuropathy. Alpha-lipoic acid improved symptom-focused outcomes including total symptom score, neurological disability score, and global satisfaction, with a dose-response trend for symptom scores. It did not clearly improve lower-limb impairment scores, vibration threshold, or nerve-conduction outcomes. The findings support a symptom-relief framing rather than a strong nerve-repair claim.

alpha-lipoic-acid-SRC-002Systematic review and network meta-analysis.
Sourceopen_in_new

Prado MB Jr, Adiao KJB. Ranking Alpha Lipoic Acid and Gamma Linolenic Acid in Terms of Efficacy and Safety in the Management of Adults With Diabetic Peripheral Neuropathy: A Systematic Review and Network Meta-analysis. Can J Diabetes. 2024;48(4):233-243.e10. doi:10.1016/j.jcjd.2024.01.007. PMID:38295879.

Population: Adults with diabetic peripheral neuropathy across 11 studies included in the network meta-analysis.

Dose protocol: Alpha-lipoic acid 600 mg/day versus placebo and gamma-linolenic acid across 11 RCTs in diabetic peripheral neuropathy.

Key findings: ALA 600 mg/day significantly reduced Total Symptom Scores versus placebo. GLA had the highest probability of being best (52.7%), but both were safe and effective. No tolerability differences between ALA and control groups.

Notes: Most current network meta-analysis (2024) comparing ALA against an active comparator. Confirms ALA efficacy at 600 mg/day for diabetic neuropathy with good tolerability.

Paper content

This 2024 network meta-analysis compared alpha-lipoic acid and gamma-linolenic acid for diabetic peripheral neuropathy across 11 RCTs. Both ALA at 600 mg/day and GLA significantly reduced Total Symptom Scores versus placebo. GLA had the highest probability (52.7%) of being the best treatment. Gastrointestinal disturbances were the primary adverse events for both treatments, but no tolerability differences were observed between ALA and control groups. The authors concluded both compounds are safe and effective biofactors for improving diabetic neuropathy symptoms.

Guides

Setup

Help